Related Articles
Clovis Oncology (NASDAQ:CLVS)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $10.60 and last traded at $10.69, with a volume of 3245 shares traded. The stock had previously closed at $11.07.
Several brokerages have issued reports on CLVS. SunTrust Banks raised their target price on Edison International to $77.00 and gave the stock a “positive” rating in a research report on Monday, April 15th. Credit Suisse Group reissued a “buy” rating and issued a $29.00 target price on shares of Clovis Oncology in a research report on Wednesday, May 15th. Piper Jaffray Companies dropped their target price on Clovis Oncology from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Sunday, April 14th. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, JPMorgan Chase & Co. raised ROYAL MAIL PLC/ADR from an “underweight” rating to a “neutral” rating in a research note on Monday, June 3rd. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $27.44.
The business’s 50 day moving average is $13.44. The firm has a market capitalization of $571.92 million, a P/E ratio of -1.53 and a beta of 1.91. The company has a debt-to-equity ratio of 8.04, a quick ratio of 4.15 and a current ratio of 4.39.
Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.17. The company had revenue of $33.12 million for the quarter, compared to the consensus estimate of $32.10 million. Clovis Oncology had a negative return on equity of 196.39% and a negative net margin of 342.54%. The firm’s quarterly revenue was up 78.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.38) EPS. Equities research analysts expect that Clovis Oncology will post -6.76 EPS for the current fiscal year.
In related news, insider Lindsey Rolfe sold 1,728 shares of Clovis Oncology stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $14.70, for a total transaction of $25,401.60. Following the sale, the insider now owns 23,319 shares of the company’s stock, valued at approximately $342,789.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 2,452 shares of company stock worth $36,261 in the last three months. 8.30% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP bought a new stake in Clovis Oncology during the 4th quarter valued at approximately $5,641,000. Norges Bank bought a new stake in Clovis Oncology during the 4th quarter valued at approximately $8,351,000. Rice Hall James & Associates LLC raised its stake in Clovis Oncology by 5.6% during the 1st quarter. Rice Hall James & Associates LLC now owns 222,165 shares of the biopharmaceutical company’s stock valued at $5,514,000 after purchasing an additional 11,743 shares during the period. Legal & General Group Plc raised its stake in Clovis Oncology by 29.9% during the 4th quarter. Legal & General Group Plc now owns 20,457 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 4,711 shares during the period. Finally, Squarepoint Ops LLC raised its stake in Clovis Oncology by 1,049.9% during the 4th quarter. Squarepoint Ops LLC now owns 78,985 shares of the biopharmaceutical company’s stock valued at $1,419,000 after purchasing an additional 72,116 shares during the period. 93.21% of the stock is currently owned by institutional investors.
About Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Read More: What are convertible shares?
Receive News & Ratings for Clovis Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clovis Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
